Genprex Added to Russell 3000® Index
June 29 2020 - 8:16AM
Business Wire
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company developing potentially
life-changing technologies for patients with cancer and diabetes,
today announced that it was added to the Russell 3000® Index after
the market closed on Friday, June 26, 2020 as part of the 2020
Russell U.S. Indexes reconstitution.
"Genprex is excited to be a member of the Russell 3000 Index,
and we look forward to sharing our story and unique approaches for
the treatment of lung cancer and diabetes with a wider group of
investors,” said Rodney Varner, Chairman and Chief Executive
Officer of Genprex. “We believe the Company’s future is bright as
we work to secure better outcomes for patients suffering from these
serious medical conditions.”
In January 2020, Genprex was awarded U.S. FDA Fast Track
designation for use of GPX-001 (quaratusugene ozeplasmid) combined
with Tagrisso® (osimertinib) for the treatment of non-small cell
lung cancer (NSCLC) patients with EGFR mutations whose tumors
progressed after treatment with Tagrisso alone. The Company also
signed in early 2020 an exclusive license agreement with the
University of Pittsburgh for a preclinical diabetes gene therapy
candidate that has the potential to cure Type 1 and Type 2
diabetes. Earlier this year, the Company significantly strengthened
its balance sheet through “at the market” capital raises without
warrants, plus the exercise by investors of most outstanding
Company warrants, aggregating approximately $28 million in proceeds
to the Company. The funds will support the Company’s research and
development programs and other corporate uses and initiatives,
which could include strategic transactions.
The Russell 3000 Index includes the 3,000 publicly traded
companies on the Nasdaq and NYSE exchanges with the largest market
capitalizations. FTSE Russell, a leading global index provider,
determines membership for its Russell indexes primarily by
objective, market-capitalization rankings and style attributes
(i.e. growth or value). Each June, the Russell 3000 index is
reconstituted to reflect market capitalization changes over the
prior year. This closely watched market event impacts more than $9
trillion in investor assets benchmarked to or invested in products
based on the Russell U.S. indices.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with
cancer and diabetes. Genprex’s technologies are designed to
administer disease-fighting genes to provide new treatment options
for large patient populations with cancer and diabetes who
currently have limited treatment options. Genprex works with
world-class institutions and collaborators to in-license and
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. The Company’s lead
product candidate, GPX-001 (quaratusugene ozeplasmid), is being
evaluated as a treatment for non-small cell lung cancer (NSCLC).
GPX-001 has a multimodal mechanism of action that has been shown to
interrupt cell signaling pathways that cause replication and
proliferation of cancer cells; re-establish pathways for apoptosis,
or programmed cell death, in cancer cells; and modulate the immune
response against cancer cells. GPX-001 has also been shown to block
mechanisms that create drug resistance. In January 2020, the U.S.
Food and Drug Administration granted Fast Track Designation for
GPX-001 for NSCLC in combination therapy with osimertinib
(AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose
tumors progressed after treatment with osimertinib alone. For more
information, please visit the Company’s web site at www.genprex.com
or follow Genprex on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of GPX-001, alone and in combination with
targeted therapies and/or immunotherapies, and whether our other
potential product candidates, including our gene therapy in
diabetes, advance into clinical trials; the success of our
strategic partnerships, including those relating to manufacturing
of our products; the timing and success at all of obtaining FDA
approval of GPX-001 and our other potential product candidates
including whether we receive fast track or similar regulatory
designations; costs associated with developing our product
candidates and whether patents will ever be issued under patent
applications that are the subject of our license agreements. These
and other risks and uncertainties are described more fully under
the caption “Risk Factors” and elsewhere in our filings and reports
with the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200629005151/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024